Contrast-Induced Nephropathy (CIN) / Post-Contrast Acute Kidney Injury (PC-AKI)

Terminology Clarification

• PC-AKI (Post-Contrast AKI): Any deterioration in renal function within 48 hours of intravascular iodinated contrast, regardless of cause - a correlative diagnosis.
• CIN (Contrast-Induced Nephropathy): A causative subset of PC-AKI where the contrast is directly responsible. It excludes AKI from other concurrent insults (infection, nephrotoxic drugs, etc.).

Definition

• Serum creatinine rise ≥ 0.5 mg/dL (absolute), or ≥ 25% above baseline, within 48 hours of contrast - persisting 2-5 days.

1. SCr rise ≥ 0.3 mg/dL (> 26.4 µmol/L)
2. SCr rise ≥ 50% (1.5x baseline)
3. Urine output ≤ 0.5 mL/kg/h for ≥ 6 hours

Pathophysiology

• Biphasic hemodynamic response: brief initial vasodilation (seconds to minutes) followed by prolonged vasoconstriction.
• Medullary hypoxia is worsened by contrast-induced increase in blood viscosity reducing vasa recta flow.
• Osmotic diuresis increases sodium delivery to the thick ascending loop of Henle, raising oxygen consumption for reabsorption.

• Reactive oxygen species (ROS) mediate proximal tubular injury (evidenced by low-molecular-weight proteinuria).
• Activation of the aldose reductase-fructokinase pathway (stimulated by hyperosmolarity) in the proximal tubule.
• Uricosuria may contribute to tubular injury.
• High osmolality of contrast agents amplifies both mechanisms.

Risk Factors

Key point: IV contrast CT in patients with eGFR > 30 mL/min/1.73 m² carries very low CIN risk. Intra-arterial contrast (e.g., cardiac catheterisation) poses substantially higher risk due to larger required volumes and direct delivery to renal arteries.

GFR Thresholds for Risk Stratification

• ESUR (European Society of Urogenital Radiology): eGFR < 45 as the threshold for elevated risk.
• Canadian Association of Radiologists: Risk starts at eGFR < 45, significantly increases at eGFR < 30.

Prevention Strategies

1. Hydration / Volume Expansion (Most Important)

• Normal saline (0.9% NaCl) at 1-1.5 mL/kg/h for at least 6 hours before AND 6 hours after contrast administration.

• 3 mL/kg/h for 1 hour before, then 1 mL/kg/h for 6 hours after.

• Mix 154 mEq/L sodium bicarbonate in 1L D5W; give 3 mL/kg IV bolus over 1 hour pre-procedure, then 1 mL/kg/h for 6 hours post-procedure.
• Rationale: urinary alkalinization reduces hydroxyl radical generation.
• However, the PRESERVE trial (large multicenter RCT) found no benefit of bicarbonate over normal saline. The 2018 ACR guidelines do not recommend bicarbonate as preferred over saline.

• IV hydration is preferred (certainty of volume delivery); oral hydration is an acceptable alternative in outpatients with eGFR 30-45 when IV is impractical, but the evidence base is weaker.
• In heart failure patients: withhold diuretics the day before and day of contrast; delay contrast until acute decompensation resolves.

2. Choice of Contrast Agent

• Use low-osmolar contrast media (LOCM) (e.g., iopamidol/Isovue, iohexol/Omnipaque) - standard of care; high-osmolar agents (HOCM) are no longer used intravascularly due to higher adverse effect profiles.
• Iso-osmolar agents (e.g., iodixanol) have not shown clear superiority over LOCM in IV studies.
• Minimize contrast volume - limit dose, especially in high-risk patients. Avoid contrast dose > 3-4 mL/kg or above the maximum contrast dose formula (5 mL × body weight (kg) / SCr).

3. Timing Between Contrast Studies

• Allow at least 24 hours between contrast-enhanced studies (time for normal-GFR kidneys to excrete contrast). In CKD, this interval should be longer.
• Avoid repeat contrast-enhanced CT < 24 hours in high-risk patients.

4. Withhold Nephrotoxic and Haemodynamically-Active Drugs

• Withhold NSAIDs, ACE inhibitors/ARBs, diuretics 24-48 hours before contrast in high-risk patients (controversial but commonly recommended).
• Withhold metformin in eGFR < 60 mL/min before contrast, restart 48 hours after if kidney function is stable (to prevent lactic acidosis in the setting of AKI, not directly nephroprotective).
• Discontinue any other concurrent nephrotoxins where clinically feasible.

5. N-Acetylcysteine (NAC)

• Antioxidant thiol; mechanistic rationale: scavenges ROS, vasodilator.
• Oral dose: 600 mg twice daily the day before and day of contrast.
• IV dose (emergency): 150 mg/kg bolus over 30 min pre-procedure, then 50 mg/kg over 4 hours.
• Evidence: Conflicting. Large RCTs (including the ACT trial) and meta-analyses show inconsistent results. The ACR does not classify NAC as proven. However, given low cost and minimal side-effect profile, some centres continue to use it alongside IV hydration.

6. Other Pharmacological Agents (Emerging/Investigational)

7. RenalGuard System

• Matched urine output-guided hydration device that maintains high urine output (≥ 300 mL/h) during contrast procedures.
• A 2025 systematic review (PMID 40099270) found it beneficial in CKD patients undergoing cardiac interventions.
• Not widely available; reserved for high-risk catheterisation lab patients.

8. Consider Alternative Imaging

• Non-contrast CT for many indications
• Ultrasound for vascular and renal assessment
• MRI (note: gadolinium-based agents are contraindicated in eGFR < 30 due to nephrogenic systemic fibrosis risk with certain linear chelates)

Clinical Course & Management of Established CIN

1. Continue aggressive IV hydration (unless volume overloaded).
2. Stop all nephrotoxins.
3. Monitor electrolytes, urine output, daily creatinine.
4. Manage complications of AKI - hyperkalaemia, metabolic acidosis, fluid overload, uraemia.
5. Renal replacement therapy (dialysis/haemofiltration) if: refractory hyperkalaemia, acidosis, fluid overload, or severe uraemia. Prophylactic dialysis to remove contrast is not recommended (contrast clears faster than dialysis can remove it, and dialysis itself carries risks).
6. Follow-up renal function at 1 week and 1 month to confirm recovery.

Patients who develop CIN have longer hospitalisation, higher short-term mortality, and higher rates of cardiac/neurologic events compared to matched controls - though some of this association may reflect confounding by underlying comorbidity severity rather than CIN causality.

Summary Algorithm

Patient requiring contrast study
         |
         ├── Assess eGFR
         |
         ├── eGFR > 45 → Routine; no specific prevention needed
         |
         ├── eGFR 30-45 → IV hydration (NS 1 mL/kg/h x 6h pre + post)
         |                 Low-osmolar contrast; minimise volume
         |                 Withhold nephrotoxins
         |                 Consider NAC (600 mg PO BID x 2 days)
         |
         └── eGFR < 30 → Above PLUS consider alternative imaging
                          Discuss with nephrology
                          Inpatient monitoring post-procedure

Recent Evidence Update (2024-2026)

• SGLT2 inhibitors pre-PCI (meta-analysis 2025, PMID 41366914): Pre-procedure SGLT2 inhibitor use in AMI patients undergoing PCI was associated with reduced CIN incidence. Mechanism likely involves tubuloglomerular feedback normalisation. Not yet in major guidelines but biologically plausible.
• Nicorandil (meta-analysis 2025, PMID 40340567): Showed potential benefit in coronary angiography; larger trials needed.
• Left Ventricular End-Diastolic Pressure (LVEDP) (systematic review 2026, PMID 38349134): Elevated LVEDP is independently associated with CIN risk in coronary angiography patients and may guide periprocedural hydration intensity.
• The concept that IV contrast routinely causes clinically significant nephropathy in patients with preserved renal function has been substantially challenged by propensity-matched studies - risk may have been significantly overstated historically, particularly for IV (as opposed to intra-arterial) administration.